Predictive Value of Lesions for Relapses in Relapsing-remitting Multiple Sclerosis

References

1. ↵
   Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MR analysis results of a multicenter, randomized, double-blind, placebo-controlled trial: UBC MS/MR Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662-667

   Abstract/FREE Full Text
2. ↵
   Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998;121:3-24

   Abstract/FREE Full Text
3. ↵
   Miller DH, Barkhof F, Nauta JJ. Gadolinium enhancement increases the sensitivity of MR in detecting disease activity in multiple sclerosis. Brain 1993;116:1077-1094

   Abstract/FREE Full Text
4. ↵
   Miller DH. Guidelines for MR monitoring of the treatment of multiple sclerosis: recommendations of the US Multiple Sclerosis Society's task force. Mult Scler 1996;1:335-338

   PubMed
5. ↵
   Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 1999;111:35-44

   CrossRefPubMedWeb of Science
6. ↵
   Truyen L, van Waesberghe JH, van Walderveen MA, et al. Accumulation of hypointense lesions (“black holes”) on T1 spin-echo MR correlates with disease progression in multiple sclerosis. Neurology 1996;47:1469-1476

   Abstract/FREE Full Text
7. ↵
   Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37-45

   CrossRefWeb of Science
8. ↵
   Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993;2:121-145

   PubMed
9. ↵
   Poser CM. Exacerbations, activity, and progression in multiple sclerosis. Arch Neurol 1980;37:471-474

   CrossRefPubMedWeb of Science
10. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231

    CrossRefPubMedWeb of Science
11. Filippi M, Horsfield MA, Ader HJ, et al. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 1998;43:499-506

    CrossRefPubMedWeb of Science
12. Tofts PS. Standardisation and optimisation of magnetic resonance techniques for multicentre studies. J Neurol Neurosurg Psychiatry 1998;64:S37-S43
13. ↵
    Barkhof F, Filippi M, van Waesberghe JH, Campi A, Miller DH, Ader HJ. Interobserver agreement for diagnostic MR criteria in suspected multiple sclerosis. Neuroradiology 1999;41:347-350

    CrossRefPubMedWeb of Science
14. ↵
    Filippi M, Rovaris M, Capra R, et al. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis: implications for phase II clinical trials. Brain 1998;121:2011-2020

    Abstract/FREE Full Text
15. ↵
    O'Riordan J, Gawne Cain M, Coles A, et al. T1 hypointense lesion load in secondary progressive multiple sclerosis: a comparison of pre versus post contrast loads and of manual versus semi automated threshold techniques for lesion segmentation. Mult Scler 1998;4:408-412

    Abstract/FREE Full Text
16. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994;344:9-13

    CrossRefPubMedWeb of Science
17. Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A 1996;93:1716-1720

    Abstract/FREE Full Text
18. ↵
    Koudriavtseva T, Thompson AJ, Fiorelli M, et al. Gadolinium enhanced MR predicts clinical and MR disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;62:285-287

    Abstract/FREE Full Text
19. ↵
    Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging of relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet 1999;353:964-969

    CrossRefPubMedWeb of Science
20. ↵
    van Walderveen MA, Truyen L, van Oosten BW, et al. Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: relation to inflammatory activity. Arch Neurol 1999;56:345-351

    CrossRefPubMedWeb of Science
21. ↵
    Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-440

    CrossRefPubMedWeb of Science
22. Miller DH. Multiple sclerosis: use of MR in evaluating new therapies. Semin Neurol 1998;18:317-325

    CrossRefPubMedWeb of Science
23. Molyneux PD, Filippi M, Barkhof F, et al. Correlations between monthly enhanced MR lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 1998;43:332-339

    CrossRefPubMedWeb of Science
24. ↵
    Koziol JA, Wagner S, Adams HP. Assessing information in T2-weighted MR scans from secondary progressive MS patients. Neurology 1998;51:228-233

    Abstract/FREE Full Text
25. Adams HP, Wagner S, Sobel DF, et al. Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients. Eur Neurol 1999;42:52-63

    CrossRefPubMed